QRX 004
Alternative Names: QRX-004Latest Information Update: 20 Jun 2022
At a glance
- Originator Quoin Pharmaceuticals
- Class Skin disorder therapies; Small molecules
- Mechanism of Action Collagen modulators; Serine protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Epidermolysis bullosa
Most Recent Events
- 15 Jun 2022 Quoin Pharmaceuticals entered into licensing and distribution agreement with Hong Kong WinHealth Pharma Group Ltd. for QRX 004
- 04 Jan 2022 QRX 004 is available for licensing as of 31 Dec 2021. https://quoinpharma.com/partnerships/
- 31 Dec 2021 Quoin Pharmaceuticals plans a registrational trial in Epidermolysis bullosa in USA